Quick Summary:
In the rapidly advancing healthcare and medical devices sector, having comprehensive, timely and accurate information is crucial to staying a step ahead. The Next Generation Sequencing (NGS) Tests pipeline report provides just that by offering in-depth analysis of the cutting-edge NGS technologies under development. With NGS being a high-throughput alternative to traditional DNA sequencing methods, understanding its diverse types, stages of development, and clinical trial data can yield valuable insights for your strategic planning.
The report also gives a competitive edge by identifying emerging players who are potentially developing strong product portfolios in the NGS Tests arena. It further assists in planning market-entry and expansion strategies leveraging the detailed analysis of the major players' promising pipelines. Stay updated with recent industry developments and formulate significant competitor information to gain that essential competitive advantage with this report. Empower your decision-making process with this invaluable tool in the world of medical device innovation.
Speak directly to the analyst to clarify any post sales queries you may have.
Next generation sequencing (NGS) refers to high-throughput methods for DNA sequencing that are not Sanger-based.
Note:: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Next Generation Sequencing (NGS) Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Next Generation Sequencing (NGS) Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment/industry
Reasons to Buy
The report enables you to:
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Next Generation Sequencing (NGS) Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- AccuraGen Inc
- ACT Genomics Co LTD
- Adaptive Biotechnologies Corp
- Almac Diagnostic Services Ltd
- Amoy Diagnostics Co Ltd
- AnchorDx Medical Co Ltd
- ArcherDx Inc
- Berry Oncology Corp
- BGI Genomics Co Ltd
- Biocartis Group NV
- Biodesix Inc
- BioLink
- bioTheranostics Inc
- Boston University
- Buhlmann Laboratories AG
- Burning Rock Biotech Ltd
- Cardiff Oncology Inc
- Cerba HealthCare SAS
- DCGen Co Ltd
- DiaGyn Ltd
- Eiken Chemical Co Ltd
- Epic Sciences Inc
- Epigenomics AG
- First Genetics JCS
- Flomics Biotech
- Foundation Medicine Inc
- Freenome Inc
- Gencurix Co., Ltd.
- Geneseeq Technology Inc
- Genetron Health (Beijing) Co Ltd
- Genomic Health Inc
- GigaGen Inc
- HTG Molecular Diagnostics Inc
- Illumina Inc
- Immunovia AB
- Inivata Ltd
- Insight Genetics Inc
- InVivoScribe Technologies Inc
- IvyGene Diagnostics
- Laboratory Corp of America Holdings
- Lucence Diagnostics Pte Ltd
- Mega Genomics Ltd
- MolecularMD Corp
- Myriad Genetics Inc
- NGeneBio Co Ltd
- Novigenix SA
- Novomics Co Ltd
- NuGEN Technologies Inc
- NuProbe Global
- OncoDNA SA
- OncoSpire Genomics
- OncXerna Therapeutics Inc
- OrigiMed Inc
- Otsuka Medical Devices Co Ltd
- Pasteur Institute
- Personal Genome Diagnostics Inc
- Pillar Biosciences Inc
- Predictive Biosciences Inc (Inactive)
- Qiagen NV
- Quantgene Inc
- RealSeq Biosciences Inc
- Rhodx Inc
- Roche Diagnostics International Ltd
- Silicon Biosystems S.p.A.
- Sophia Genetics SA
- Spectrum Solutions LLC
- Sysmex Corp
- Sysmex Inostics GmbH
- Tempus Health Inc
- Thermo Fisher Scientific Inc
- Trivitron Healthcare Pvt Ltd
- TwinStrand Biosciences Inc
- University of Chicago
- University of Michigan Rogel Cancer Center
- University of Texas Health Science Center at Houston
- Vyant Bio Inc
